Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival
Genome Medicine(2020)
Abstract
Background Tumor mutational burden (TMB, the quantity of aberrant nucleotide sequences a given tumor may harbor) has been associated with response to immune checkpoint inhibitor therapy and is gaining broad acceptance as a result. However, TMB harbors intrinsic variability across cancer types, and its assessment and interpretation are poorly standardized.
Methods Using a standardized approach, we quantify the robustness of TMB as a metric and its potential as a predictor of immunotherapy response and survival among a diverse cohort of cancer patients. We also explore the additive predictive potential of RNA-derived variants and neoepitope burden, incorporating several novel metrics of immunogenic potential.
Results We find that TMB is a partial predictor of immunotherapy response in melanoma and non-small cell lung cancer, but not renal cell carcinoma. We find that TMB is predictive of overall survival in melanoma patients receiving immunotherapy, but not in an immunotherapy-naive population. We also find that it is an unstable metric with potentially problematic repercussions for clinical cohort classification. We finally note minimal additional predictive benefit to assessing neoepitope burden or its bulk derivatives, including RNA-derived sources of neoepitopes.
Conclusions We find sufficient cause to suggest that the predictive clinical value of TMB should not be overstated or oversimplified. While it is readily quantified, TMB is at best a limited surrogate biomarker of immunotherapy response. The data do not support isolated use of TMB in renal cell carcinoma.
* αCTLA4
: Anti-cytotoxic T-lymphocyte-associated protein 4
αPD1
: Anti-programmed cell death protein 1
AUC
: Area Under the Curve
COAD
: Colon Adenocarcinoma
GATK
: Genome Analysis Toolkit
GTEx
: Genotype Tissue Expression
HLA
: Human Leukocyte Antigen
Indel
: Insertion or deletion
KIRC
: Kidney Renal Clear Cell Carcinoma
kma
: Keep Me Around
LUAD
: Lung Adenocarcinoma
LUSC
: Lung Squamous Cell Carcinoma
MHC
: Major Histocompatiblity Complex
MMR
: Mismatch Repair
NSCLC
: Non Small Cell Lung Cancer
PRAD
: Prostate Adenocarcinoma
RCC
: Renal Cell Carcinoma
RI
: Retained intron
RNA-seq
: RNA sequencing
ROC
: Receiver Operating Characteristic
SKCM
: Skin Cutaneous Melanoma
SRA
: Sequence Read Archive
TCGA
: The Cancer Genome Atlas
THCA
: Thyroid carcinoma
TMB
: Tumor Mutational Burden
TPM
: Transcripts Per Million
TVB
: Tumor Variant Burden
UCEC
: Uterine Corpus Endometrial Carcinoma
VCF
: Variant Call Format
WES
: Whole Exome Sequencing
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined